@article{fdi:010091374,
  title = {{W}hich diagnostic test to use for {T}esting and {T}reatment strategies in {P}lasmodium vivax low-transmission settings : a secondary analysis of a longitudinal interventional study},
  author = {{T}r{\'e}hard, {H}. and {M}usset, {L}. and {L}azrek, {Y}. and {W}hite, {M}. and {P}elleau, {S}. and {M}ueller, {I}. and {D}jossou, {F}. and {S}anna, {A}. and {L}andier, {J}ordi and {G}audart, {J}. and {M}osnier, {E}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground {T}he lack of sensitive fi eld tests to diagnose blood stages and hypnozoite carriers prevents {T}esting and {T}reatment ({TAT}) strategies to achieve {P}lasmodium vivax elimination in low-transmission settings, but recent advances in {P}olymerase {C}hain {R}eaction ({PCR}) and serology position them as promising tools. {T}his study describes a {PCR}-based {TAT} strategy ({PCRTAT}) implemented in {S}aint {G}eorges ({SGO}), {F}rench {G}uiana, and explores alternative strategies (sero{TAT} and sero{PCRTAT}) to diagnose and treat {P}. vivax carriers. {M}ethods {T}he {PALUSTOP} cohort study implemented in {SGO} ({S}eptember 2017 to {D}ecember 2018) screened participants for {P}. vivax using {PCR} tests and treated positive cases. {S}erology was also performed. {P}assive detection of {P}. vivax infection occurred during follow-up. {P}articipants were categorised into overlapping treatment groups based on 2017 {PCR} and serological results. {S}trategies were described in terms of participants targeted or missed, primaquine contraindications (pregnancy, {G}6{PD} severe or intermediate deficiency), fi ciency), and sociodemographic characteristics. {F}indings {I}n 2017, 1567 inhabitants were included, aged 0-92 - 92 years. {A} total of 90 (6%) were {P}. vivax carriers and 390 seropositive (25%). {PCRTAT} missed 282 seropositive individuals while sero{TAT} would have missed 21 {PCR}-positive cases. {P}rimaquine contraindications ranged from 12% to 17% across strategies. {I}nterpretation {S}erology and {PCR} are promising tools for targeted treatment strategies in {P}. vivax low-transmission settings, when fi eld compatible sensitive tests will be available. {B}oth seem necessary to capture blood stages and potential hypnozoite carriers, while avoiding mass treatment. {H}owever, high primaquine contraindications rates need consideration for successful elimination.},
  keywords = {{P}lasmodium vivax ; {L}ow transmission ; {S}erology ; {E}limination ; {R}elapse},
  booktitle = {},
  journal = {{L}ancet {R}egional {H}ealth : {A}mericas},
  volume = {38},
  numero = {},
  pages = {100883 [12 p.]},
  ISSN = {2667-193{X}},
  year = {2024},
  DOI = {10.1016/j.lana.2024.100883},
  URL = {https://www.documentation.ird.fr/hor/fdi:010091374},
}